AU6451998A - Screening and treatment using complement regulator or receptor proteins - Google Patents

Screening and treatment using complement regulator or receptor proteins

Info

Publication number
AU6451998A
AU6451998A AU64519/98A AU6451998A AU6451998A AU 6451998 A AU6451998 A AU 6451998A AU 64519/98 A AU64519/98 A AU 64519/98A AU 6451998 A AU6451998 A AU 6451998A AU 6451998 A AU6451998 A AU 6451998A
Authority
AU
Australia
Prior art keywords
screening
treatment
receptor proteins
complement regulator
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64519/98A
Inventor
David L. Enfield
G. Michael Hass
Robert J. Kinders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bard Diagnostic Sciences Inc
Original Assignee
Bard Diagnostic Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bard Diagnostic Sciences Inc filed Critical Bard Diagnostic Sciences Inc
Publication of AU6451998A publication Critical patent/AU6451998A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
AU64519/98A 1997-03-06 1998-03-06 Screening and treatment using complement regulator or receptor proteins Abandoned AU6451998A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3861597P 1997-03-06 1997-03-06
US81248197A 1997-03-06 1997-03-06
US60038615 1997-03-06
US08812481 1997-03-06
PCT/US1998/004492 WO1998039659A1 (en) 1997-03-06 1998-03-06 Screening and treatment using complement regulator or receptor proteins

Publications (1)

Publication Number Publication Date
AU6451998A true AU6451998A (en) 1998-09-22

Family

ID=26715383

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64519/98A Abandoned AU6451998A (en) 1997-03-06 1998-03-06 Screening and treatment using complement regulator or receptor proteins

Country Status (4)

Country Link
EP (1) EP0972200A1 (en)
JP (1) JP2001515589A (en)
AU (1) AU6451998A (en)
WO (1) WO1998039659A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015259A1 (en) * 1998-09-10 2000-03-23 The University Of Virginia Patent Foundation Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
JP2002543044A (en) 1999-03-01 2002-12-17 ジェネンテック・インコーポレーテッド Antibodies for cancer treatment and diagnosis
AU2001271656A1 (en) * 2000-06-29 2002-01-14 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
JP2018128408A (en) * 2017-02-10 2018-08-16 東ソー株式会社 Antibody aggregate formation prediction method
CN115261401B (en) * 2022-08-25 2023-10-20 杭州博岳生物技术有限公司 Method for developing bladder tumor antigen monoclonal antibody by using yeast cell surface display technology

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
GB8726230D0 (en) * 1987-11-10 1987-12-16 Rosen H Antibodies
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
DE3830271A1 (en) * 1988-09-06 1990-03-15 Goetze Otto MEDIUM WITH IMMUNE SUPPRESSIVE EFFECT
US5322838A (en) * 1988-11-16 1994-06-21 Brigham & Women's Hospital Use of INHIB (the C3 β-chain) in the detection and inhibition of inflammation
EP0512733A2 (en) * 1991-05-03 1992-11-11 Washington University Modified complement system regulator
JP3562834B2 (en) * 1994-06-01 2004-09-08 孝夫 辻 Test method for DAF molecules in stool
ATE273388T1 (en) * 1994-09-08 2004-08-15 Imutran Ltd ALTERED HUMAN C3 PROTEINS

Also Published As

Publication number Publication date
JP2001515589A (en) 2001-09-18
WO1998039659A1 (en) 1998-09-11
EP0972200A1 (en) 2000-01-19

Similar Documents

Publication Publication Date Title
AU7470398A (en) Titanium crystal and titanium
AU6030398A (en) Human proteins
AU5721798A (en) Human mage-like protein
AU6241698A (en) Tace-like and matrilysin-like polypeptides
AU7472196A (en) Alpha-helix mimetics and methods relating thereto
IL118375A0 (en) Rhesus OB protein and DNA
AU2871899A (en) Human receptor proteins; related reagents and methods
AU4480697A (en) Human nm23-like protein
AU3305197A (en) Non-activated receptor complex proteins and uses thereof
AU3451397A (en) Modified protein g and fragments thereof
AU6451998A (en) Screening and treatment using complement regulator or receptor proteins
AU2408397A (en) Ob protein receptor genes and use of the same
AU9017598A (en) Human frezzled-like protein
AU5369396A (en) Rest protein and dna
AU6035398A (en) Human c5a-like receptor
HUP9801330A3 (en) Novel pka-binding proteins and uses thereof
AU6330598A (en) Novel human transmembrane 4 superfamily protein
AU8019494A (en) Human endothelin-bombesin receptor
AU9786498A (en) Human receptor proteins; related reagents and methods
AU7572398A (en) New human transmembrane protein
GB9519865D0 (en) Protein
AU2659799A (en) Human receptor proteins
AU6050198A (en) Novel human cystatin-like protein
AU6891998A (en) Human tumor-associated membrane protein
AU7259898A (en) Human smt-3 like protein